Statins remain a cornerstone of cholesterol management, but newer nonstatin treatments provide additional options for people who cannot tolerate statins or need further LDL cholesterol reduction. The 2026 ACC/AHA dyslipidemia guideline identifies treatments such as ezetimibe, bempedoic acid, and PCSK9 inhibitors as evidence-based nonstatin options for appropriate patients.
The choice of treatment depends on cardiovascular risk, LDL cholesterol levels, previous treatment response, and individual circumstances.
Common options include:
The 2026 guideline specifically highlights ezetimibe, bempedoic acid, and PCSK9 monoclonal antibodies among evidence-based nonstatin options.
Nonstatin medications may be considered when a patient has difficulty tolerating statins or when LDL cholesterol is not adequately controlled.
Factors that may influence the decision include:
The goal is not necessarily to replace statins for everyone. In many cases, a nonstatin medication may be added to a tolerated statin to provide additional LDL reduction.
Medication is only one part of cholesterol management. Heart-healthy lifestyle habits remain important alongside appropriate cholesterol-lowering treatment.
Helpful habits include:
Lifestyle changes may support healthier cholesterol levels and overall cardiovascular health.
Bempedoic acid has become a more prominent nonstatin option in recent cholesterol guidance. Clinical evidence has shown cardiovascular benefit in patients who are unable to tolerate statin therapy, and the 2026 guideline gives bempedoic acid a more prominent role among nonstatin treatments.
It is not appropriate for everyone, however, and potential adverse effects and individual medical factors need to be considered by a healthcare professional.
PCSK9 inhibitors can produce substantial reductions in LDL cholesterol and may be considered for patients at sufficiently high cardiovascular risk who need additional LDL lowering.
These medicines work differently from statins by helping the liver remove more LDL cholesterol from the bloodstream.
The 2026 guideline also incorporates newer nonstatin approaches, while some newer therapies continue to have outcomes evidence under evaluation.
A person should not stop or replace a prescribed statin without speaking with their healthcare professional. Statins remain the foundation of lipid-lowering therapy for many patients, and alternatives are generally selected according to individual cardiovascular risk and treatment response.
If side effects are suspected, a clinician may evaluate whether the symptoms are related to the medication and determine whether a different dose, statin, or nonstatin approach is appropriate.
The latest 2026 cholesterol guidance does not recommend that everyone replace statins. Instead, it expands the role of nonstatin treatments such as ezetimibe, bempedoic acid, and PCSK9 inhibitors for people who need additional LDL reduction or cannot tolerate statins. The best treatment depends on individual cardiovascular risk, cholesterol levels, medical history, and tolerance of available therapies. This article is for informational purposes only and should not replace advice from a qualified healthcare professional.